Cargando…

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death

BACKGROUND: The Akt/mammalian target of rapamycin (mTOR) signalling pathway serves as a critical regulator of cellular growth, proliferation and survival. Akt aberrant activation has been implicated in carcinogenesis and anticancer therapy resistance. Piperlongumine (PL), a natural alkaloid present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makhov, P, Golovine, K, Teper, E, Kutikov, A, Mehrazin, R, Corcoran, A, Tulin, A, Uzzo, R G, Kolenko, V M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929888/ https://www.ncbi.nlm.nih.gov/pubmed/24434432 http://dx.doi.org/10.1038/bjc.2013.810

Ejemplares similares

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-κB-independent, proteasome-mediated mechanism
por: Golovine, Konstantin, et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
por: Ogata, A, et al.
Publicado: (2008)

TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt
por: Szegezdi, E, et al.
Publicado: (2006)

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells
por: Sudhagar, S, et al.
Publicado: (2011)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death
por: Hotfilder, M, et al.
Publicado: (2005)

The pro-apoptotic role of autophagy in breast cancer
por: Suman, S, et al.
Publicado: (2014)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma
por: Makhov, Peter, et al.
Publicado: (2018)

Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
por: Wang, Hongfei, et al.
Publicado: (2018)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway
por: Ghebeh, H, et al.
Publicado: (2014)

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
por: Hu, X F, et al.
Publicado: (2007)

Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours
por: White, D E, et al.
Publicado: (2010)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
por: Isham, C R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1bj548rvt6p7tu6h8ids887evk